ClinicalTrials.gg
CompletedNCT06635057T-RAMUpdated May 22, 2026

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

A Phase 4 interventional study of Tirzepatide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
166
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
21st of 43
166 · median 160
Started
2024
with 5 others
Phase 4
10 of 43
4 open now
Registered
33rd of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 6 that started in 2024, is one of 10 in phase 4, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Ramadan
  • Fasting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of uncontrolled Type 2 Diabetes based on the World Health Organization classification or other locally applicable diagnostic standards, and who intend to fast during Ramadan
  • Have ≥7% within 30 days prior to screening
  • Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve
  • Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening
  • Have ≥25 kilograms per square meter (kg/m2) at screening

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes or gestational diabetes
  • Have a history of chronic or acute pancreatitis
  • Have acute or chronic hepatitis
  • Have evidence of a significant, uncontrolled endocrine abnormality
  • Have a history of an active or untreated
  • Have Functional Classification IV congestive heart failure
  • Have been treated with insulin within two weeks prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants will receive tirzepatide subcutaneously (SC)

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from Start of Ramadan (SoR)

Secondary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from SoR

  2. Number of Hypoglycemic Events

    Time frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from SoR

  3. Number of Self-Reported Gastrointestinal (GI) Adverse Events

    Time frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from SoR

  4. Percentage of Participants Achieving HbA1c <7%

    Time frame: Baseline (20 to 8 weeks Before Ramadan), Week 4-8 from SoR

  5. Change from SoR to End of Ramadan (EoR) in the 5-Level European Quality of Life 5 Dimensions (EQ-5D-5L)

    Time frame: SoR (Week 0), EoR (Week 4)

07

Study locations

29 sites
  • Al Moosa Specialist Hospital
    Al Ahasa, 36342, Saudi Arabia
  • National Guard Hospital-King Abdulaziz Medical City
    Alahsa, 36428, Saudi Arabia
  • King Abdulaziz Medical City-Jeddah
    Jeddah, 21423, Saudi Arabia
  • King Fahad Armed Forces Hospital Jeddah
    Jeddah, 21433, Saudi Arabia
  • King Faisal Specialist Hospital & Research Center
    Jeddah, 21499, Saudi Arabia
  • Saudi Airlines Medical services
    Jeddah, Saudi Arabia
  • King Faisal Specialist Hospital and Research Center Madina
    Madinah, 42523, Saudi Arabia
  • King Saud University
    Riyadh, 11472, Saudi Arabia
  • Osepdale Fatebenefratelli e Oftalmico
    Riyadh, 11525, Saudi Arabia
  • Al Dallah Hospital
    Riyadh, 11652, Saudi Arabia
  • Sulaiman Habib Olaya
    Riyadh, 12214, Saudi Arabia
  • Specialized Medical Center Hospital
    Riyadh, 12311, Saudi Arabia
  • Dallah Namar Hospital
    Riyadh, 14963, Saudi Arabia
  • Dr. Sulaiman Al Habib Hospital As Suwaidi
    Riyadh, 14963, Saudi Arabia
  • Dr. Sulaiman Al Habib Medical Complex Arrayan Saudi Arabia
    Riyadh, Saudi Arabia
  • Lifecare Hospital
    Abu Dhabi, 133500, United Arab Emirates
  • Tawam Hospital
    Abu Dhabi, 34761, United Arab Emirates
  • Imperial College London Diabetes Center
    Abu Dhabi, United Arab Emirates
  • NMC Abu Dhabi
    Abu Dhabi, United Arab Emirates
  • Rashid Centre for Diabetes and Research
    Ajman, United Arab Emirates
  • Thumbay University Hospital
    Ajman, United Arab Emirates
  • Emirates Hospital Dubai
    Dubai, 0000, United Arab Emirates
  • Aster Clinics
    Dubai, United Arab Emirates
  • Dubai Diabetes Center
    Dubai, United Arab Emirates
  • Dubai Hospital
    Dubai, United Arab Emirates
  • Medcare Hospital
    Dubai, United Arab Emirates
  • Mediclinic City Hospital
    Dubai, United Arab Emirates
  • Rashid Hospital.
    Dubai, United Arab Emirates
  • Medcare Hospital
    Sharjah city, 0000, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Apr 2026, 18 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 18 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 10, 2024
StartActual
Oct 11, 2024
Primary completionActual
Apr 15, 2026
CompletionActual
Apr 15, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06635057
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Oct 11, 2024
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
May 22, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion